Is Asciminib covered by medical insurance?

Asciminib (Asciminib) is indicated for adult patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) in chronic phase (CP) who have been pretreated with two or more TKIs, and for adults with Ph+CML-CP with T315I mutation. The first indication is approved under the U.S. Food and Drug Administration (FDA)Accelerated Approval Program based on the 24-week MMR rate; continued approval of the first indication may depend on verification and description of clinical benefit from confirmatory evidence.

Aceminib exerts its therapeutic activity by inhibiting the oncogenic protein responsible for the proliferation of chronic myelogenous leukemia. It is the first FDA-approved treatment for chronic myelogenous leukemia that binds to the myristoyl group of ABL. This new mechanism of action, also known as STAMP inhibitors in the scientific literature, may help resolve drug resistance in chronic myelogenous leukemia patients previously treated with two or more TKIs and overcome mutations in the defective BCR-ABL1 gene that are associated with overproduction of leukemia cells. Aceminib has also been shown to limit off-target activity in preclinical studies.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in medical insurance. The original drug of Asiminib currently sold overseas is very expensive. Generic drugs of Asiminil are also produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rate effects), and the price is relatively cheap. For more drug information and specific prices, please consult Yaode’s medical consultant.